Europe Pharmacogenomic Testing for Psychiatry Market Industry Trends and Forecast to 2034: Segmented by (Test, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
Europe · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$89.1 MnPlaceholder estimate
Estimate 2025$97.0 Mn20% of the global market
Projected 2034$209.0 Mn 115.4%Adds $112.0 Mn over 9 forecast years
CAGR 2025–20348.9%Faster than 63% of 180 Medical Devices markets here
Key players5
Europe is 20.04% of the global market.
Among regions, the largest is North America at $233.8 Mn.
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The Europe Pharmacogenomic Testing for Psychiatry Market Analysis Executive Summary
Pharmacogenomic tests for psychiatry look at a person's genes to help doctors choose antidepressants and other mental health medicines that are likely to work.
Key segments of the pharmacogenomic Testing for Psychiatry market include test (Multi-Gene Panels and Single-Gene Tests) and application (Depression, Anxiety and ADHD).
Europe Pharmacogenomic Testing for Psychiatry market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Europe Pharmacogenomic Testing for Psychiatry Market Dynamics
Market Growth Drivers
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the pharmacogenomic Testing for Psychiatry market. Governments and employers are investing more in mental health care.
Opportunity
Digital tools, new drug classes and care built into primary care and workplaces give the pharmacogenomic Testing for Psychiatry market strong room to grow worldwide.
Market Restraints
Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the pharmacogenomic Testing for Psychiatry market.
Competitive Landscape for Pharmacogenomic Testing for Psychiatry Market in Europe
The pharmacogenomic Testing for Psychiatry market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Pharmacogenomic Testing for Psychiatry Market in Europe
Pharmacogenomic Testing for Psychiatry in Europe: rules and payment
In the EU, medical devices need CE marking under the Medical Device Regulation (MDR); for most devices, an independent notified body checks them first.[1] In the countries we cover here, medical devices are regulated by ANSM (France)[2], BfArM (Germany)[3], Ministry of Health (Italy)[4], Roszdravnadzor (Russia)[5], AEMPS (Spain)[6], MHRA (UK)[7], IGJ (Netherlands)[8], FAMHP (Belgium)[9], Swissmedic (Switzerland)[10], Läkemedelsverket (Sweden)[11], Danish Medicines Agency (Denmark)[12], URPL (Poland)[13] and TITCK (Turkey)[14]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.[15]
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how pharmacogenomic Testing for Psychiatry products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Europe.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Test
4.2 By Application
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Myriad Genetics
7.2 Genomind
7.3 OneOme
7.4 Tempus
7.5 Thermo Fisher Scientific
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The pharmacogenomic Testing for Psychiatry market can be segmented based on various criteria, including test, application and end user. Here's a breakdown of the market segmentation
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
WHO Global Health Observatory.
Fetched 20 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
How big is the Pharmacogenomic Testing for Psychiatry market in Europe?
Placeholder estimate: about $97.0 Mn in 2025, rising to about $209.0 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Pharmacogenomic Testing for Psychiatry market in Europe growing?
Placeholder estimate: about 8.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Pharmacogenomic Testing for Psychiatry market report cover?
The report splits the market by test (Multi-Gene Panels, Single-Gene Tests), application (Depression, Anxiety, ADHD, Bipolar Disorder) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Pharmacogenomic Testing for Psychiatry market?
Key players include Myriad Genetics, Inc., Genomind, OneOme, Tempus and Thermo Fisher Scientific Inc..
What is driving the Pharmacogenomic Testing for Psychiatry market?
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the pharmacogenomic Testing for Psychiatry market. Governments and employers are investing more in mental health care.
Who regulates Pharmacogenomic Testing for Psychiatry in Europe?
In the EU, medical devices need CE marking under the Medical Device Regulation (MDR); for most devices, an independent notified body checks them first. Source: European Commission, medical devices. Checked 14 Nov 2026.
How is healthcare paid for in Europe?
Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines. Source: European Commission, health technology assessment. Checked 14 Nov 2026.
How much research is published on Pharmacogenomic Testing for Psychiatry?
PubMed lists 6 papers on Pharmacogenomic Testing for Psychiatry added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.